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Abstract: Microbial resistance to conventional antibiotics is one of the most outstanding medical
and scientific challenges of our times. Despite the recognised need for new anti-infective agents,
however, very few new drugs have been brought to the market and to the clinic in the last three
decades. This review highlights the properties of a new class of antibiotics, namely dendrimeric
peptides. These intriguing novel compounds, generally made of multiple peptidic sequences linked
to an inner branched core, display an array of antibacterial, antiviral and antifungal activities, usually
coupled to low haemolytic activity. In addition, several peptides synthesized in oligobranched form
proved to be promising tools for the selective treatment of cancer cells.
Keywords: antimicrobial peptides; dendrimers; peptidomimetics; biofilms; antiviral; antifungal;
antitumor; model membranes; biophysical methods; NMR; molecular dynamics
1. The Rising Tide of Antimicrobial Resistance
Antimicrobial resistance is an alarming threat to public health at the global level. Current
estimates of the associated burden vary greatly depending on the method of data collation and
analysis [1], but a recent report commissioned by the United Kingdom government estimated that,
by 2050, 10 million people will die every year due to antimicrobial resistance unless appropriate
countermeasures are taken [2]. A range of infectious microbial pathogens are already resistant to most
classes of clinically usable antibiotics, strongly reducing the choices of alternative treatments, that
sometimes are simply non-existent [3,4]. Increasing rates of multi-drug resistance in bacterial strains
that cause common infections associated with healthcare settings and/or community-acquired have
been reported worldwide. Furthermore, an array of important viral, fungal and protozoan pathogens
are also progressively more resistant to currently available therapies. For instance, artemisinin
resistance in malaria is spreading, and increasing levels of transmitted anti-human immunodeficiency
virus (HIV) drug resistance have been detected among patients starting antiretroviral treatment [5].
“A post-antibiotic era—in which common infections and minor injuries can kill—far from being an
apocalyptic fantasy, is instead a very real possibility for the 21st century”, commented a recent World
Health Organization (WHO) report on antimicrobial resistance [5]. Besides the health burden that this
situation poses, the societal and economic impact of antimicrobial resistance is wide and of worrying
proportions. Antimicrobial resistance is a composite phenomenon due to a host of circumstances,
but its rise has certainly been hastened by the selective pressure exerted by the use and misuse of
antimicrobial agents in both animals and humans. The natural environment is also a vast source
of antibiotic resistance, since it “harbors a diverse reservoir of resistance determinants, including
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resistance genes and the mobile genetic elements that operate as vectors for them” [6]. In addition to
the need to preserve the effectiveness of existing antibiotics through a wiser use of their properties,
the scarcity of new antimicrobial agents on the horizon to replace those that have become ineffective
calls for the urgent quest for new anti-infective substances to be developed and deployed in the clinic.
2. Dendrons to the Rescue!
Clearly, no magic bullets exist here. Rather, several strategies aimed at replenishing our waning
arsenal of anti-infective agents must be pursued. A group of substances that has drawn considerable
and growing attention in the last few decades is made of antimicrobial peptides (AMPs), a vast
array of molecules active to various degrees against bacteria, enveloped viruses, protozoa and fungi.
Synthesized on ribosomes and gene-encoded, AMPs are a key component of the innate immune system
of all metazoans and are usually cationic, fold into amphipathic structures and destabilize and/or
permeate the plasma membranes of target cells [7–11]. Dedicated web-based repositories, such as the
Antimicrobial Peptide Database [12], strive to keep up the pace of discovery of new peptides from
many natural sources.
Although AMPs have good potential to be a viable alternative to conventional antibiotics, thanks
for example to their tendency to rarely elicit antimicrobial resistance, they are not devoid of drawbacks.
Indeed, because of their peptidic nature, they are characterized by scarce bioavailability and suffer
from poor proteolytic stability, two features that have severely hampered clinical progress to date.
In the attempt to overcome these disadvantages, various modifications have been introduced to develop
synthetic analogues that mimic the properties of AMPs [13,14]. AMPs found in nature remain the
principal model for these modifications, which are generally focused on their main physico-chemical
and membrane activity-related properties, such as positive charge and amphiphilic nature.
Among the most promising synthetic or semi-synthetic approaches to mimic the properties of
AMPs, multimeric peptides have proven to be an intriguing variation. As reported more extensively
below, several examples of peptidic dendrimers endowed with antimicrobial properties were recently
reported. These molecules were in general designed following the so-called multiple antigenic peptide
(MAP) system, first evolved in the 1980s as immunogens for producing site-specific polyclonal and
monoclonal antibodies [15,16], where multiple peptide sequences can be added using standard solid
phase chemistry to an inner core that consists of a divalent lysine (Lys) whose α- and ε-amines double
geometrically with each branching generation (Figure 1). Other types of peptide dendrimers are
functionalized at the periphery with peptide chains, or grafted with either unnatural amino acids
or organic groups as the branching core and peptides or proteins attached as surface functional
groups [17]. Figure 1 shows examples of dendrimeric peptides built around Lys residues at their
core, with L-Leucine as branching units, or developed to structurally resemble depsipeptides. Overall,
dendrimeric peptides show increased activity compared to monomeric counterparts, which is probably
attributable to their multivalent nature, i.e., a higher local concentration (effective molarity) of bioactive
units for dendrimeric molecules, as well as reduced susceptibility to the action of proteases and
peptidases, a fact attributed to the nature of the branching core that with its steric hindrance would limit
the cleavage rates of plasma peptidases, thus improving the peptides’ pharmacokinetics properties.
The multivalency of peptide dendrimers appears to be functional to the design of AMPs for their
ability to amplify cationic charges and hydrophobic clusters as the number of dendrimer branches
increases, mimicking the mechanisms of action through which high-ordered antimicrobial peptides
exert their membranolytic effects [18]. Since the antimicrobial potency of AMPs is by no means related
to their length, with several examples of very active short peptides being known [19], the selection
of short sequences for the design of antimicrobial dendrimers is desirable. Besides involving smaller
production costs and less cumbersome synthetic routes, peptide dendrimers with low molecular mass
have the additional advantage of being less immunogenic than high-molecular-mass dendrimers.
Thus, short dendrimeric peptides may well be a useful and peculiar biopolymer design for effecting
an array of membranolytic activities.
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3. Dendrimeric Peptides as New Antibacterial Drugs
Most studies on the development of dendrimeric peptides as therapeutic agents, so far, have
focused on bacterial targets. This is understandable, of course, given the clinic relevance of this type of
infection. Of particular interest is the activity of several new compounds against multi-drug resistant
(MDR) bacteria and biofilms. Concern regarding biofilm-associated infections is swiftly increasing
worldwide, indeed, as biofilms are inherently tolerant and resistant to most antimicrobial agents.
Furthermore, they have a tendency to grow on the surfaces of medical devices, considerably expanding
the risk of microbial dissemination within the host and the further spread of hospital-acquired
infections [20,21]. The need to deploy additional bactericidal measures is particularly urgent for
biofilms, and many AMPs, both of a dendrimeric nature or not, have been tested for their ability to
target specific features of sessile bacterial communities [22]. A dedicated database, the Biofilm-active
AMPs database (BaAMPs) [23], is available, which reports information on the antibiofilm activity of
AMPs in an organized framework.
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About a decade ago, in one of the first steps along this research avenue, Neville Kallenbach and
colleagues have synthesized a group of dendrimeric peptides containing multiple R (Arg) W (Trp)
dipeptides [24]. The dendrimer with the best activity, named (RW)4D, was found to preferentially
kill Gram-negative bacteria relative to Gram-positive strains, probably through a membranolytic
mechanism. As noted by the researchers, both arginine (Arg) and tryptophan (Trp) residues occur
frequently in AMPs, often in the same sequence (e.g., indolicidin), with Arg providing cationic charges
that are crucial for peptide binding to the negatively-charged cell walls and membranes of bacterial
targets and the lipophilic Trp anchoring peptides to the outer leaflet of the membrane and perturbing its
integrity. More recently, the activity of the novel antimicrobial peptide dendrimer G3KL, with natural
lysine and leucine residues alternating in the branches, against a number of Acinetobacter baumannii and
Pseudomonas aeruginosa strains was reported as compared to the activities of standard antibiotics [25].
Overall, G3KL displayed a promising antibacterial activity against a large collection of difficult-to-treat
isolates, including several producing carbapenemases, that are frequently faced in the contemporary
international clinical scenario; in addition, the compound had little toxicity for red blood cells
in vitro [25]. G3KL, which is believed to act as a membrane-disrupting compound, is a peptide
dendrimer of third generation with the sequence (KL)8(KKL)4(KKL)2KKL (K = branching lysine),
structured as multiple short dipeptides connected by branching Lys residues, and has been derived
through a process of sequence optimization of a hit compound spotted by screening a combinatorial
library of dendrimers, by means of a custom-made high-throughput screening assay [26,27].
Another interesting group of antimicrobial dendrimeric peptides was derived from a short linear
sequence, identified in the first place by selecting a random phage library against Escherichia coli
cells: a subsequent rational modification and optimization process permitted obtaining the compound
known as SB041, a tetra-branched peptide [28]. Further modifications of the primary sequence led to
SB056, with a dimeric dendrimer scaffold. In SB056, the core is restricted to a single Lys residue, and
only two copies of the same highly cationic 10-mer polypeptide are present, coupled to an octanamide
tail linked to the C-terminus. This compound is highly active against Gram-negative microorganisms,
with an intensity comparable to that of colistin and polymyxin B; however, it demonstrates a more
extensive range of action, with some activity also against Gram-positive bacteria [29]. The use of
a range of biophysical tools like circular dichroism (CD), nuclear magnetic resonance (NMR) and
molecular dynamics (MD) simulations, joined with membrane affinity assays by lipid monolayer
surface pressure experiments, uncovered that this intriguing peptide was indeed membrane-active
by folding into a β-type conformation in lipidic environments [29]. A close inspection of the primary
sequence [WKKIRVRLSA] of the peptidic part of the dendrimeric SB056 reveals a distinct pattern of
alternating hydrophilic and hydrophobic amino acids, with the exception of the first two residues
(Figure 2).
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Figure 2. Schematic representation of the branched peptides SB056 and βSB056 (see the main text for
the details). Two peptide branches are bonded to the α- and ε-amino group of a lysine residue, i.e., the
linker, respectively. An 8-aminooctanamide tail is bonded to the C-terminus of the linker. The residue
type is colour coded as follows: hydrophobic in yellow, positively charged in blue and polar uncharged
residues in cyan. The positively-charged N-termini are represented by the blue square with the white
cross in the middle. The two residues, the position of which was exchanged moving from SB056 to
βSB056, are red bordered. From [30]. Reproduced with permission.
Given the ascertained β-type conformation of SB056, further modification of the peptidic
part of the dendrimeric SB056 was then performed by interchanging the first two residues to
obtain a more regular β-type conformation with a full pattern of alternating hydrophilic and
hydrophobic amino acids; thus, a perfectly amphipathic analogue [KWKIRVRLSA] was designed
(Figure 2). Noteworthy, such improvement of the amphipathic profile resulted in the formation
of more ordered and stable β-strands when the monomeric, linear peptide interacted with odel
e branes and a stronger anti icrobial activity against both Gra -positive and Gra -negative
bacterial strains (Figure 3) [31]. Further results obtained against Escherichia coli and Staphylococcus
aureus planktonic strains, in the presence or without salts at physiological concentrations, corroborated
the idea that the dendrimeric design is endowed with added value over the linear one, especially
at physiological ionic strength, and displayed the full impact of the higher a phipathicity obtained
through sequence optimization on improving peptide performances [32]. SB056 peptides also showed
intriguing antibiofilm properties, especially against Staphylococcus epidermidis [32]. For all peptides,
membrane affinity increased with the amount of negatively-charged lipids in model membranes
and was less influenced by the presence of salt in the case of dendrimeric peptides. Furthermore,
the amphipathically optimized analogue of SB056 displayed the highest overall affinity, even for
zwitterionic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) bilayers, clearly indicating
that, in addition to electrostatics, the distribution of hydrophobic and charged/polar residues along
the primary sequence plays a significant role in driving peptide-lipid interaction [32]. Finally,
a combination of NMR and MD simulations allowed the determination of the 3D structure of the
two SB056 analogues, unveiling a singular β hairpin-type structure determined by the peptide chains
only, with the octanamide tail eventually available for further functionalization to add new potential
properties without affecting the structure (Figure 4) [30].
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Figure 3. Summary of SB056 peptide-lipid interactions. The proportion of anionic lipids in
the vesicles is increased from top to bottom (as indicated by the red arrow). The behaviour of
the original monomeric, linear peptide SB056-lin, is represented on the left-hand side and the
sequence-optimized βSB056-lin on the right. Black arrows of different lengths and thicknesses
are used to indicate the different binding equilibria. SB056-lin binds only to anionic bilayers, and
in a not-so-well-ordered β-stranded conformation. The sequence optimized βSB056-lin, on the
other hand, binds even to zwitterionic bilayers and forms regular β-strands that self-assemble
into extended β-sheets when the negative charge of the bilayer exceeds the electro-neutrality
of the peptide-lipid system. POPC: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPG:
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol). From [31]. Reproduced with permission.
Another interesting example of dendrimeric peptide with antibiofilm activity is 2D-24, a new
synthetic compound containing RWR (Arg-Trp-Arg) and RTtbR(2) tripeptide branches [33]. This
molecule was found able to kill biofilm cells of two strains of Pseudomonas aeruginosa, namely the
wild-type PAO1 and its mucoid mutant PDO300, in a dose-dependent manner, and also to be active
against multidrug-tolerant persister cells of both strains [33].
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deficiency syndrome (AIDS) patients: these infections are indeed a serious cause of morbidity and 
mortality for these groups. It seems that, in this case, dendrimers exercised their inhibitory effect by 
preventing the attachment of virions to heparan sulphate on the cell surface, a so far unreported 
antiviral mechanism that could render SB105 and SB105-A10 attractive candidates as examples of 
an original class of antiviral drugs [35]. The same research group reported successful use of the 
same dendrimeric peptides SB105 and SB105-A10 in binding heparan sulphates on cell surfaces and 
inhibiting the infectivity of genital types of human papillomavirus (HPV) in both 293TT and 
keratocarcinoma cells [36], an important finding for the potential development of a topical 
microbicide against sexually-transmitted viral infections. More recently, SB105 and SB105-A10 were 
shown to be able to directly inhibit herpes simplex virus 1 (HSV-1) and HSV-2 in vitro replication, 
even in conditions mimicking the physiological properties of the vagina, such as low pH values and 
in the presence of 10% human serum proteins. According to researchers, this new antiviral activity 
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dodecylphosphocholine (DPC)/sodium dodecyl sulphate (SDS) 3:1. These two detergents are
synergistic and form mixed micelles, with the selected molar ratio being typically employed to mimic a
bacterial plasma membrane [11]. First, a computer-simulated annealing was applied in a vacuum (a,d)
with the distance restraints derived from experimental NOEs (cross peaks from Nuclear Overhauser
Effect spectroscopy). Then, an equilibrium molecular dynamics (MD) simulation was run with the same
restraints and in the presence of explicit water and detergent molecules. The last frame after 100 ns
is shown in (b,e). Finally, a second 100-ns MD run was performed after releasing all restraints, and
the last frame is shown in (c,f). The backbone of the α-and ε-branch is represented with a differently
coloured trace, green and purple, respectively. The atoms of the detergents are represented with the
corresponding van der Waals s heres. DPC and SDS are coloured in cyan and orange, respectively.
From [30]. Reproduced with permission.
4. ir ses a F gal at oge s as argets
I a itio to targeting bacterial pathogens, peptide-derivatized endrimers have the capacity for
other anti-i fective applications, including as antiviral agents [34]. For instance, a study has recently
demonstrated that the tetrabranched SB105 and its derivative SB105-A10 (Figure 5) were capable
of inhibiting the replication of several strains of human cyto egalovirus (HCMV) in both primary
fibroblasts and endothelial cells [35]. HCMV is a challenging pathogen for recipients of bone marrow
and solid-organ transplants and among immunocompromised acquired immune eficiency syndrome
(AIDS) patients: these infections are indeed a serious cause of morbidity and mortality for these groups.
It seems that, in this case, dendri ers exercised their inhibitory effect by preventing the attachment
of virions to heparan sulphate on the cell surface, a so far unreported antiviral mechanism that
could render SB105 and SB105-A10 attractive candidates as examples of an original class of antiviral
drugs [35]. The same research group reported successful use of the same dendrimeric peptides SB105
and SB105-A10 in binding heparan sulphates on cell surfaces and inhibiting the infectivity of genital
types of human papillomavirus (HPV) in both 293TT and keratocarcinoma cells [36], an important
finding for the potential develop ent of a topical microbicide against sexually-transmitted viral
infections. More recently, SB105 and SB105-A10 were shown to be able to directly inhibit herpes
simplex virus 1 (HSV-1) and HSV-2 in vitro replication, even in conditions mimicking the physiological
properties of the vagina, such as low pH values and in the presence of 10% human serum proteins.
According to researchers, this new antiviral activity is based on the binding of the dendrimers to the
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glycosaminoglycan moiety of cell surface heparan sulphate proteoglycans (HSPGs), thereby blocking
virion attachment to target cells [37]. The same mechanism seems to apply for the ability of SB105-A10
in contrasting infection of several cell lines by respiratory syncytial virus (RSV), which also interacts
with HSPGs to enter target cells [38]. The potential of SB105-A10 to act as an antiviral agent was
also evaluated using a model of the epithelial tissue of the human respiratory tract, made of cultured
tracheal/bronchial epithelial cells; SB105-A10 markedly reduced RSV infectivity and showed no
evidence of inducing cytotoxicity or proinflammatory effects, making this peptide an interesting lead
for further improvement as an RSV inhibitor to be dispensed by aerosol delivery, the researchers
concluded [38].
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Another interesting example of a peptide dendrimer endowed with antiviral activity belongs 
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amphiphilic polar ad deriv d from th (Lys)Lys(Lys) dendron and containing a C8 or C12 chain t
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synthas [42]. “Introduction of a lipid tail at C-end (particul rly C12) yielded several compounds with
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enhanced antimicrobial potency, low hemotoxicity and selectivity shifted towards yeasts of the Candida
genus”, the researchers commented. More recently, the same team synthesized a bunch of novel
peptide dendrimers rich in Trp and with an amphiphilic fold, variable in structure and hydrophobicity,
and tested their activity versus various Candida species and strains. A specific lead, dendrimer 14,
containing four Trp residues and a dodecyl tail, was found to be particularly active, causing membrane
damage at fungicidal concentration (16 µg/mL) and inducing both cell death in Candida cells by both
apoptosis and necrosis [43]. Confocal microscopy observations showed that dendrimer 14 affects the
morphogenesis and biofilm viability of Candida, destroying mature biofilm by acting negatively on the
germination and reducing hyphae formation and also inhibited the biofilm formation [43]. Another
compound with a branched structure, D186, containing four Trp residues, exhibited an anti-Candida
action mode associated with a reduced virulence in terms of adhesive ability and pathogenic potential
related to the expression of the SAP5 gene and morphogenetic factors EFG1 and CPH1 [44].
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5. Turning Branched Peptides into Antitumor Therapeutics
In dendrimeric peptides, there is more than meets the eye. A clear demonstration is the recent
opening of a new research avenue, aimed at transforming protease-resistant multimeric peptides in
tumour targeting agents. In particular, the group of Luisa Bracci at the University of Siena has focused
on the potential applications of tetra-branched peptides (NT4) containing the human regulatory
peptide neurotensin (NT) sequence. Since neurotensin receptors are overexpressed in several human
tumours, like prostate, colon, pancreatic and small-cell lung cancer, researchers have explored the
possibility of using NT4 conjugated to different functional units for tumour treatment and imaging.
Drugs, such as 6-mercaptopurin, combretastatin A-4 and monastrol, were conjugated to
oligobranched neurotensin peptides through several linkers, and different human cancer cell lines were
used to study the mode-of-release and cytotoxicity [45]. Results showed that branched peptides armed
with combretastatin A-4 displayed significant activity against pancreas and prostate human cancer
cells [45]. Furthermore, NT4 conjugated to methotrexate or 5-fluorodexoyuridine, which resulted in
having the best in vitro cytotoxic activity, were tested in tumour xenografted mice models and were
shown to reduce tumour growth by 60% and 50%, respectively [46]. Thus, “branched peptides may
increase the selectivity of small molecules towards tumor cells, acting as ‘Trojan horses’ that selectively
transport chemotherapy drugs into tumor cells, since they have the ability of turning nonspecific
cytotoxic drugs into tumor-selective agents, which presently have a limited use in oncology due to
their low selectivity and high nonspecific toxicity” [47].
More recent observations led researchers to understand that the significantly higher binding of
NT4 peptides relative to the monomeric counterparts to cancer cell lines and cancer surgical samples
is generated by a modification of selectivity that becomes directed toward additional membrane
receptors specifically expressed by a number of different human cancers. In detail, the multimeric
design provides NT4 with the ability to bind heparin and receptors belonging to the low density
lipoprotein receptor (LDLR) family, which is well known to have a role in cancer biology [48].
Systematically modifying the neurotensin sequence in NT4 peptides led to the detection of a multimeric
positively-charged motif mediating the interaction with both heparin and endocytic receptors [48].
A further therapeutic target for the use of branched peptides and anti-cancer agents has been bladder
cancer, which ranks ninth in worldwide cancer incidence. NT4 was tested on HT-1376 and T24 bladder
cancer cell lines in vitro and on human cancer samples obtained from patients that underwent radical
cystectomy or endoscopic transurethral resection of the bladder, comparing results with those obtained
with the healthy tissue counterpart of the same patients to evaluate its ability to recognize specific
membrane receptors and to be internalized. NT4 conjugated to fluorophores distinguished cancer and
healthy tissues with good statistical significance, and NT4 conjugated to methotrexate or gemcitabine
was found to be cytotoxic for human bladder cancer cell lines at micromolar concentrations [49].
6. Dendrimers in Perspective
“Antibiotic resistance and the collapse of the antibiotic research-and-development pipeline
continue to worsen despite our ongoing efforts on all these fronts. If we're to develop countermeasures
that have lasting effects, new ideas that complement traditional approaches will be needed,” remarked
David Gilbert and colleagues on the evolution of antibiotic resistance and strategies for combating
it [50]. Making the need for action more urgent is the recent emergence of Escherichia coli resistance
to colistin (polymyxin E), often used as the last resort for the treatment of infections caused
by multidrug-resistant gram-negative bacteria; due to the mcr-1 gene, this resistance is rapidly
spreading [51,52].
As this review has strived to demonstrate, dendrimeric peptides have the potential to contribute
to the development of those next-generation antibiotics we need so badly, offering virtually infinite
synthetic possibilities coupled to the tendency to hit novel targets in their microbicide action and to
evoke little resistance. In addition, we are probably only beginning the exploration of their versatility
as clinically-applicable agents, namely in anti-cancer therapies.
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As far as antibiotic resistance is concerned, needless to say, refilling the pipeline with new drugs
is just one component of a global, comprehensive strategy that must be enforced in order to address
the microbial resistance crisis. Other key interventions include the prevention of infections in the
first place, the elimination or restriction of the use of antibiotics to promote livestock growth, the
sequestration of host nutrients to prevent microbial access to nutrients, the development of other
therapies focusing on host targets rather than microbial targets to avoid selective pressure driving
resistance, and much more [50].
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